Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, April 23, 2012 ACHILLION PHARMACEUTICALS (NASDAQ:ACHN), Down By 7.05% ($0.56) From $8.004 After BUYINS.NET Report Predicted Stock Would Go Dow
April 23, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Thursday, April 19th 2012 stating that ACHILLION PHARMACEUTICALS (NASDAQ:ACHN) was expected to go Down due to the Bearish conditions presented in the following report. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=achn&id=266101
At the time this story was written, ACHILLION PHARMACEUTICALS (NASDAQ:ACHN) is Down By $0.56 (7.05%) since the BUYINS.NET report was released.
The movement of stock prices in the days and weeks leading to and following specific fundamental or technical events may follow a predictable pattern. Many companies stock price histories show random or unpredictable movements around certain events. But some seem to repeat the same pattern quarter after quarter, year after year. We use powerful computers to uncover those events and correlations to generate predictions with high probabilities of generating very specific returns within very specific time periods.
The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php
ACHILLION PHARMACEUTICALS (NASDAQ:ACHN) - Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. The company focuses on the development of antivirals for the treatment of chronic hepatitis C; and the development of antibacterials for the treatment of resistant bacterial infections. Its drug candidate pipeline includes ACH-1625, a protease inhibitor, which is in phase 1/b clinical trials for the treatment of chronic hepatitis C infections; ACH-1095, a NS4A antagonist that is in late-stage preclinical studies for the treatment of chronic hepatitis C infections; and ACH-2684, a protease inhibitor, which is in late stage preclinical testing. The companys other product candidates comprise ACH-702, which is in preclinical stage for the treatment of serious bacterial infections; and Elvucitabine that is in phase II clinical trials for the treatment of HIV infection. The company has a collaboration arrangement with Gilead Sciences, Inc. to develop and commercialize compounds for the treatment of chronic hepatitis C, which inhibit viral replication through a mechanism of action. Achillion Pharmaceuticals, Inc. was founded in 1998 and is based in New Haven, Connecticut.
About BUYINS.NET
BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:
REGULATORY & COMPLIANCE NEWS
Friction Factor market-maker surveillance system tracking Level II market-makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements"
RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO
INVESTMENTS & TRADING
SqueezeTrigger -- 30 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.
Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.
Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.
Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.
Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.
GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.
DISCLAIMER:
BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies specifically for this report, but may have been compensated up to $1,200 per month in the past for unrelated data or report services. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.
Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net
- WOPRAI
- support@woprai.com